This is the authors' abstract. We don't add key points for this paper.
= 10) of tofacitinib treated RA patients who self-reported adherent behaviour. The assay measured tofacitinib in all samples above the LLOQ demonstrating the potential of the assay to sensitively measure biochemical adherence in real-world patient samples. This method for detection of adherence has the potential to be a more objective measure that could be used in the future in the clinic but will require further studies to explore factors that may influence measurement of drug levels, such as clinical characteristics of patients.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Church et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: